查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1698319

氣霧劑給藥裝置市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Aerosol Drug Delivery Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 134 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球氣霧劑藥物輸送設備市場價值為 302 億美元，預計 2025 年至 2034 年期間的複合年成長率為 6.3%。氣喘和慢性阻塞性肺病 (COPD) 等呼吸系統疾病的盛行率日益上升，推動了對先進藥物輸送解決方案的需求。隨著空氣污染水平持續惡化、吸煙率居高不下以及工作場所有害化學物質的接觸增加，越來越多的人患有慢性呼吸系統疾病，需要可靠的治療方案。此外，隨著醫療保健越來越以患者為中心，人們越來越傾向於方便、經濟高效和在家治療的解決方案，這進一步推動了氣霧劑給藥裝置的採用。

氣霧劑給藥裝置市場 - IMG1

製藥公司正致力於創新，開發效率更高、使用更方便的吸入器和霧化器。整合數位追蹤和監控功能的智慧吸入器正在成為該領域的遊戲規則改變者，幫助患者堅持治療計劃。政府和醫療保健組織也在推動改善呼吸系統治療的可近性，預計這將對市場擴張做出重大貢獻。同時，全球人口老化，加上呼吸道感染和過敏負擔的增加，進一步鞏固了臨床和家庭對氣霧劑給藥裝置的需求。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 302億美元
預測值 549億美元
複合年成長率 6.3%

市場分為定量吸入器 (MDI)、乾粉吸入器 (DPI) 和霧化器。其中，MDI 的成長速度最快，預計到 2034 年複合年成長率為 6.5%。這些吸入器已成為治療氣喘、慢性阻塞性肺病和囊性纖維化等慢性呼吸道疾病的必需品。它們價格實惠、便於攜帶且設計方便用戶使用，因此成為患者和醫療保健提供者的首選。被診斷患有慢性呼吸系統疾病的人數不斷增加，推動了對 MDI 的需求，製藥公司也紛紛投資研發以提高其效率。

在分銷方面，醫院藥房領域預計將成為成長最快的領域，複合年成長率為 6.6%，到 ​​2034 年將產生 247 億美元的產值。醫院藥局在確保患者能夠使用各種氣霧劑給藥裝置（包括 MDI、DPI 和霧化器）進行住院和門診治療方面發揮著至關重要的作用。因嚴重呼吸系統疾病而入院的人數不斷增加，這增加了對這些設備的需求。此外，人們對污染、工作場所危害以及吸煙率上升的日益擔憂，不斷增加對有效呼吸系統治療的需求。

2024 年美國氣霧劑給藥設備市場價值為 101 億美元，預計 2025 年至 2034 年期間的複合年成長率為 5.5%。由於空氣品質差、過敏原暴露增加以及吸煙率高，呼吸系統疾病的盛行率不斷上升，導致對先進吸入治療的需求激增。製藥公司正在透過引入旨在提高療效和患者依從性的尖端藥物輸送系統來應對。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 呼吸系統疾病盛行率上升
      • 拓展呼吸系統疾病以外的應用
      • 非侵入性藥物輸送的需求不斷成長
      • 吸煙和生活方式相關疾病的增加
      • 技術進步
      • 電子商務和網路藥局的快速擴張
    • 產業陷阱與挑戰
      • 先進吸入裝置成本高昂
      • 嚴格的監管要求
      • 副作用和藥物沉積問題
  • 成長潛力分析
  • 監管格局
  • 技術格局
  • 差距分析
  • 波特的分析
  • PESTEL 分析
  • 未來市場趨勢
  • 價值鏈分析

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 策略儀表板

第5章：市場估計與預測：按產品，2021 - 2034 年

  • 主要趨勢
  • 定量吸入器（MDI）
    • 加壓MDI
    • 呼吸驅動的MDI
    • 軟霧吸入器
  • 乾粉吸入器（DPI）
    • 單劑量DPI
    • 多劑量DPI
  • 霧化器
    • 噴射霧化器
    • 網狀霧化器
    • 超音波霧化器
    • 霧化器配件

第6章：市場估計與預測：按應用，2021 - 2034 年

  • 主要趨勢
  • 慢性阻塞性肺病（COPD）
  • 氣喘
  • 囊腫纖維化
  • 其他應用

第7章：市場估計與預測：按配銷通路，2021 - 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 其他分銷管道

第8章：市場估計與預測：依最終用途，2021 - 2034 年

  • 主要趨勢
  • 醫院和診所
  • 家庭醫療保健環境
  • 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Aerogen
  • Aptar
  • AstraZeneca
  • Berry
  • beurer
  • Catalent
  • drive
  • graham field
  • MEDLINE
  • NOVARTIS
  • OMRON
  • PARI
  • Pfizer
  • Philips
  • teva
簡介目錄
Product Code: 13243

The Global Aerosol Drug Delivery Devices Market was valued at USD 30.2 billion in 2024 and is expected to grow at a CAGR of 6.3% between 2025 and 2034. The increasing prevalence of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), is fueling demand for advanced drug delivery solutions. As air pollution levels continue to worsen, smoking rates remain high, and workplace exposure to harmful chemicals increases, more individuals are developing chronic respiratory conditions, necessitating reliable treatment options. Additionally, as healthcare becomes more patient-centric, there is a growing preference for convenient, cost-effective, and at-home treatment solutions, further driving the adoption of aerosol drug delivery devices.

Aerosol Drug Delivery Devices Market - IMG1

Pharmaceutical companies are focusing on innovation to develop inhalers and nebulizers that offer superior efficiency and ease of use. Smart inhalers, integrated with digital tracking and monitoring capabilities, are becoming a game-changer in this space, helping patients adhere to their treatment plans. Governments and healthcare organizations are also pushing for improved access to respiratory treatments, which is expected to contribute significantly to market expansion. Meanwhile, an aging global population, coupled with the increasing burden of respiratory infections and allergies, is further solidifying the need for aerosol drug delivery devices in both clinical and home settings.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$30.2 Billion
Forecast Value$54.9 Billion
CAGR6.3%

The market is categorized into metered dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. Among these, MDIs are set to experience the fastest growth, with a projected CAGR of 6.5% through 2034. These inhalers have become essential in managing chronic respiratory conditions such as asthma, COPD, and cystic fibrosis. Their affordability, portability, and user-friendly design make them the preferred choice among patients and healthcare providers alike. The increasing number of individuals diagnosed with chronic respiratory diseases is driving demand for MDIs, with pharmaceutical companies investing in research and development to enhance their efficiency.

In terms of distribution, the hospital pharmacy segment is anticipated to be the fastest-growing, with a CAGR of 6.6%, generating USD 24.7 billion by 2034. Hospital pharmacies play a crucial role in ensuring patients have access to a wide range of aerosol drug delivery devices, including MDIs, DPIs, and nebulizers, for both inpatient and outpatient treatment. The rising number of hospital admissions due to severe respiratory conditions is bolstering demand for these devices. Additionally, growing concerns over pollution, workplace hazards, and increasing rates of smoking continue to amplify the need for effective respiratory treatments.

The U.S. Aerosol Drug Delivery Devices Market was valued at USD 10.1 billion in 2024 and is projected to grow at a CAGR of 5.5% between 2025 and 2034. The increasing prevalence of respiratory conditions, fueled by poor air quality, rising allergen exposure, and high smoking rates, is creating a surge in demand for advanced inhalation treatments. Pharmaceutical companies are responding by introducing cutting-edge drug delivery systems designed for enhanced efficacy and patient compliance.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of respiratory diseases
      • 3.2.1.2 Expanding applications beyond respiratory diseases
      • 3.2.1.3 Growing demand for non-invasive drug delivery
      • 3.2.1.4 Increase in smoking and lifestyle-related disorders
      • 3.2.1.5 Technological advancements
      • 3.2.1.6 Rapid expansion of e-commerce and online pharmacies
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced inhalation devices
      • 3.2.2.2 Stringent regulatory requirements
      • 3.2.2.3 Side effects and drug deposition issues
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
  • 3.10 Value chain analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Metered dose inhalers (MDIs)
    • 5.2.1 Pressurized MDIs
    • 5.2.2 Breath-actuated MDIs
    • 5.2.3 Soft mist inhalers
  • 5.3 Dry powder inhalers (DPIs)
    • 5.3.1 Single-dose DPIs
    • 5.3.2 Multi-dose DPIs
  • 5.4 Nebulizers
    • 5.4.1 Jet nebulizers
    • 5.4.2 Mesh nebulizers
    • 5.4.3 Ultrasonic nebulizers
    • 5.4.4 Nebulizer accessories

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Chronic obstructive pulmonary disease (COPD)
  • 6.3 Asthma
  • 6.4 Cystic fibrosis
  • 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Other distribution channels

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Home healthcare settings
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Aerogen
  • 10.2 Aptar
  • 10.3 AstraZeneca
  • 10.4 Berry
  • 10.5 beurer
  • 10.6 Catalent
  • 10.7 drive
  • 10.8 graham field
  • 10.9 MEDLINE
  • 10.10 NOVARTIS
  • 10.11 OMRON
  • 10.12 PARI
  • 10.13 Pfizer
  • 10.14 Philips
  • 10.15 teva